Editorial introductions
Advances in diagnosis and follow-up in kidney cancer
The staging of renal cell carcinoma
Minimally invasive nephron-sparing surgery
Probe ablative treatment for small renal masses: cryoablation vs. radio frequency ablation
Cytoreductive nephrectomy in metastatic renal cell carcinoma
Targeted therapy in renal cell carcinoma
Can we still afford bladder cancer?
Genetic susceptibility to bladder cancer with an emphasis on gene–gene and gene–environmental interactions
The detection of genetic markers of bladder cancer in urine and serum
Follow-up of nonmuscle invasive transitional cell carcinoma of the bladder: how and how often?
Prostatic biology, histologic patterns and clinical consequences of transitional cell carcinoma
Bladder preserving strategies for muscle-invasive bladder cancer
Gene therapy in bladder cancer
Molecular targeting in the treatment of either advanced or metastatic bladder cancer or both according to the signalling pathways
Healthcare economics of bladder cancer: cost-enhancing and cost-reducing factors
Current World Literature